Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates

Journal of Bone and Mineral Research

Volumn 24, Issue 11, 2009, Pages 1819-1826

  Danese, Mark D ^a   Badamgarav, Enkhe ^b   Bauer, Douglas C ^c  

^a Outcomes Insights   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Bisphosphonates; Compliance; Fractures; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HIP FRACTURE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; OSTEOPOROSIS; PATIENT COMPLIANCE; SENSITIVITY ANALYSIS; UNITED STATES; VERTEBRA FRACTURE; AGING; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG ADMINISTRATION; ECONOMICS; FRACTURE; PATHOLOGY;

AGED; AGING; BONE DENSITY CONSERVATION AGENTS; COMPUTER SIMULATION; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; MODELS, BIOLOGICAL; OSTEOPOROSIS; PATIENT COMPLIANCE; UNITED STATES;

EID: 73949136942     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090506     Document Type: Article

References (52)

1. MacLean C, Alexander A, Carter J, Chen S, Desai SB, Grossman J, Maglione M, McMahon M, McNamara M, Mojica W, Newberry S, Ranganath V, Suttorp M, Timmer M, Tringale C, Valentine D, Zhou A 2007 Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis. Comparative Effectiveness Review No. 12. (Prepared by Southern California/RAND Evidence-based Practice Center under contract No. 290-02-0003). Agency for Healthcare Research and Quality, Rockville, MD, USA.
2. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B 2003 Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216.
3. Andrade SE, Kahler KH, Frech F, Chan KA 2006 Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565-574. (Pubitemid 44336271)
4. Cramer JA, Gold DT, Silverman SL, Lewiecki EM 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023-1031. (Pubitemid 47019996)
5. Stevenson M, Jones ML, De NE, Brewer N, Davis S, Oakley J 2005 A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1-160.
6. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR 1999 Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:1215-1220. (Pubitemid 29269861)
7. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey E 2003 Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254-1260.
8. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809.
9. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D 2005 Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895-1903.
10. Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney TP, Prestwood K 2003 Nonadherence and osteoporosis treatment preferences of older women: A qualitative study. J Womens Health (Larchmt) 12:1037-1045. (Pubitemid 38072422)
11. Unson CG, Litt M, Reisine S, Mahoney-Trella P, Sheperd T, Prestwood K 2006 Adherence to calcium/vitamin D and estrogen protocols among diverse older participants enrolled in a clinical trial. Contemp Clin Trials 27:215-226.
12. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008. (Pubitemid 40064656)
13. Huybrechts KF, Ishak KJ, Caro JJ 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928.
14. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022. (Pubitemid 44175011)
15. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W 2007 The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review. BMC Musculoskelet Disord 8:97.
16. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287.
17. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E 2003 Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968.
18. Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H 2007 Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: Implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin 23:2517-2529.
19. Johnell O, Jonsson B, Jonsson L, Black D 2003 Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305-314.
20. Kanis JA, Borgstrom F, Johnell O, Jonsson B 2004 Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862-871.
21. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM 2006 The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Intern Med 166:1209-1217.
22. Schousboe JT, Nyman JA, Kane RL, Ensrud KE 2005 Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142:734-741.
23. Stevenson M, Davis S, Lloyd-Jones M, Beverley C 2007 The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess 11:1-134.
24. Strom O, Borgstrom F, Sen SS, Boonen S, Haentjens P, Johnell O, Kanis JA 2007 Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047-1061.
25. van Staa TP, Kanis JA, Geusens P, Boonen A, Leufkens HG, Cooper C 2007 The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 10:348-357.
26. U.S. Census Bureau 2006 Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2005. Available online at http://www.census.gov/. Accessed May 10, 2006.
27. Looker AC, Johnston CC Jr, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Lindsay RL 1995 Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 10:796-802.
28. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, III, Khaltaev N 2008 A reference standard for the description of osteoporosis. Bone 42:467-475.
29. Cramer JA, Amonkar MM, Hebborn A, Altman R 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453-1460.
30. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W 2006 The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: A comparison of studies in the United States, the United Kingdom, and France. Clin Ther 28:1686-1694.
31. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G 2002 Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516.
32. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G 2002 Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23:517-523.
33. Cadarette SM, Katz JN, Brookhart MA, Sturmer T, Stedman MR, Solomon DH 2008 Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture. Ann Intern Med 148:637-646.
34. U.S. Department of Labor Consumer Price Index - All Urban Cosumers Medical Care; 1995 to 1997. Available online at http://www.bls.gov. Accessed May 2, 2008.
35. Melton LJ III, Crowson CS, O'Fallon WM 1999 Fracture incidence in Olmsted County, Minnesota: Comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int 9:29-37.
36. De Laet CE, van Hout BA, Burger H, Hofman A, Pols HA 1997 Bone density and risk of hip fracture in men and women: Cross sectional analysis. BMJ 315:221-225.
37. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR 2009 Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521.
38. Stewart RB, Caranasos GJ 1989 Medication compliance in the elderly. Med Clin North Am 73:1551-1563.
39. McDonald HP, Garg AX, Haynes RB 2002 Interventions to enhance patient adherence to medication prescriptions: Scientific review. JAMA 288:2868-2879.
40. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, Stroupe KT, Wu J, Clark D, Smith F, Gradus-Pizlo I, Weinberger M, Brater DC 2007 Pharmacist intervention to improve medication adherence in heart failure: A randomized trial. Ann Intern Med 146:714-725.
41. Brennan RM, Wactawski-Wende J, Crespo CJ, Dmochowski J 2004 Factors associated with treatment initiation after osteoporosis screening. Am J Epidemiol 160:475-483.
42. National Osteoporosis Foundation 2003 Physician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation, Washington, DC, USA.
43. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial. JAMA 296:2927-2938.
44. Rasmussen JN, Chong A, Alter DA 2007 Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297:177-186.
45. Prince RL, Devine A, Dhaliwal SS, Dick IM 2006 Effects of calcium supplementation on clinical fracture and bone structure: Results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 166:869-875.
46. Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH 2007 Gaps in treatment among users of osteoporosis medications: The dynamics of noncompliance. Am J Med 120:251-256.
47. National Center for Health Statistics 2004 National Vital Statistics Reports. Probability of Death During 1-Year Intervals, 53rd ed. National Center for Health Statistics, Hyattsville, MD, USA.
48. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, III, Berger M 2000 Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739.
49. Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259.
50. Ohsfeldt RL, Borisov NN, Sheer RL 2006 Fragility fracture-related direct medical costs in the first year following a non-vertebral fracture in a managed care setting. Osteoporos Int 17:252-258.
51. Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ III 2002 Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323-330.
52. DMD America I. Analysource online. Available online at http://www.analysource.com. Accessed on May 2, 2008.